Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of d-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment

Karl Goodkin, Benedetto Vitiello, William D. Lyman, Deshratn Asthana, J. Hampton Atkinson, Peter N R Heseltine, Rebeca Molina, Wenli Zheng, Imad Khamis, Frances L. Wilkie, Paul Shapshak

Research output: Contribution to journalArticle

Abstract

D-Ala1-peptide T-amide (DAPTA) has shown neuroprotection in vitro against gp120-induced loss of dendritic arborization and is promulgated as a CCR5 antagonist. A multisite, randomized, double-blind clinical trial of DAPTA versus placebo prior to combination antiretroviral therapy conducted with human immunodeficiency virus (HIV)-1 seropositive participants having cognitive impairment showed no overall cognitive effect, though subgroups with greater impairment and CD4 cell counts of 201 to 500 cells/mm3 at baseline showed significant improvement. The objective of this study was to examine whether intranasal administration of DAPTA at a dose of 2 mg three times per day (tid) was associated with a reduction of cerebrospinal fluid (CSF) and peripheral (plasma and serum) viral load among a subgroup of participants completing 6 months of treatment. Baseline and 6-month CSF (n = 92) and peripheral (plasma n = 33; serum n = 24) viral load were measured by the Roche Ultrasensitive assay, version 1.5, with reflexive use of the AMPLICOR assay and preservation of the blind. A DAPTA treatment indicator variable was tested using generalized linear models on change in viral load. Peripheral load (combined plasma and serum) was significantly reduced in the DAPTA-treated group. No group differences in CSF viral load were found. This retrospective study on a limited subgroup of the original trial sample indicated that DAPTA treatment may reduce peripheral viral load without concomitant CSF effects. Future studies should be undertaken to confirm the existence of this result and the CSF-periphery dissociation observed with respect to HIV-1-associated cognitive-motor impairment.

Original languageEnglish (US)
Pages (from-to)178-189
Number of pages12
JournalJournal of NeuroVirology
Volume12
Issue number3
DOIs
StatePublished - Jun 2006
Externally publishedYes

Fingerprint

HIV-1
Viral Load
Placebos
Cerebrospinal Fluid
Serum
Dissociative Disorders
Intranasal Administration
Neuronal Plasticity
Therapeutics
CD4 Lymphocyte Count
Cognitive Dysfunction
peptide T amide
Linear Models
Retrospective Studies
Clinical Trials

Keywords

  • Clinical trial
  • Cognition
  • CSF
  • DAPTA
  • HIV
  • Peptide T
  • Viral load

ASJC Scopus subject areas

  • Virology
  • Clinical Neurology

Cite this

Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of d-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment. / Goodkin, Karl; Vitiello, Benedetto; Lyman, William D.; Asthana, Deshratn; Atkinson, J. Hampton; Heseltine, Peter N R; Molina, Rebeca; Zheng, Wenli; Khamis, Imad; Wilkie, Frances L.; Shapshak, Paul.

In: Journal of NeuroVirology, Vol. 12, No. 3, 06.2006, p. 178-189.

Research output: Contribution to journalArticle

Goodkin, Karl ; Vitiello, Benedetto ; Lyman, William D. ; Asthana, Deshratn ; Atkinson, J. Hampton ; Heseltine, Peter N R ; Molina, Rebeca ; Zheng, Wenli ; Khamis, Imad ; Wilkie, Frances L. ; Shapshak, Paul. / Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of d-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment. In: Journal of NeuroVirology. 2006 ; Vol. 12, No. 3. pp. 178-189.
@article{159fc6a401784895a49eb59c6ec3377e,
title = "Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of d-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment",
abstract = "D-Ala1-peptide T-amide (DAPTA) has shown neuroprotection in vitro against gp120-induced loss of dendritic arborization and is promulgated as a CCR5 antagonist. A multisite, randomized, double-blind clinical trial of DAPTA versus placebo prior to combination antiretroviral therapy conducted with human immunodeficiency virus (HIV)-1 seropositive participants having cognitive impairment showed no overall cognitive effect, though subgroups with greater impairment and CD4 cell counts of 201 to 500 cells/mm3 at baseline showed significant improvement. The objective of this study was to examine whether intranasal administration of DAPTA at a dose of 2 mg three times per day (tid) was associated with a reduction of cerebrospinal fluid (CSF) and peripheral (plasma and serum) viral load among a subgroup of participants completing 6 months of treatment. Baseline and 6-month CSF (n = 92) and peripheral (plasma n = 33; serum n = 24) viral load were measured by the Roche Ultrasensitive assay, version 1.5, with reflexive use of the AMPLICOR assay and preservation of the blind. A DAPTA treatment indicator variable was tested using generalized linear models on change in viral load. Peripheral load (combined plasma and serum) was significantly reduced in the DAPTA-treated group. No group differences in CSF viral load were found. This retrospective study on a limited subgroup of the original trial sample indicated that DAPTA treatment may reduce peripheral viral load without concomitant CSF effects. Future studies should be undertaken to confirm the existence of this result and the CSF-periphery dissociation observed with respect to HIV-1-associated cognitive-motor impairment.",
keywords = "Clinical trial, Cognition, CSF, DAPTA, HIV, Peptide T, Viral load",
author = "Karl Goodkin and Benedetto Vitiello and Lyman, {William D.} and Deshratn Asthana and Atkinson, {J. Hampton} and Heseltine, {Peter N R} and Rebeca Molina and Wenli Zheng and Imad Khamis and Wilkie, {Frances L.} and Paul Shapshak",
year = "2006",
month = "6",
doi = "10.1080/13550280600827344",
language = "English (US)",
volume = "12",
pages = "178--189",
journal = "Journal of NeuroVirology",
issn = "1355-0284",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of d-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment

AU - Goodkin, Karl

AU - Vitiello, Benedetto

AU - Lyman, William D.

AU - Asthana, Deshratn

AU - Atkinson, J. Hampton

AU - Heseltine, Peter N R

AU - Molina, Rebeca

AU - Zheng, Wenli

AU - Khamis, Imad

AU - Wilkie, Frances L.

AU - Shapshak, Paul

PY - 2006/6

Y1 - 2006/6

N2 - D-Ala1-peptide T-amide (DAPTA) has shown neuroprotection in vitro against gp120-induced loss of dendritic arborization and is promulgated as a CCR5 antagonist. A multisite, randomized, double-blind clinical trial of DAPTA versus placebo prior to combination antiretroviral therapy conducted with human immunodeficiency virus (HIV)-1 seropositive participants having cognitive impairment showed no overall cognitive effect, though subgroups with greater impairment and CD4 cell counts of 201 to 500 cells/mm3 at baseline showed significant improvement. The objective of this study was to examine whether intranasal administration of DAPTA at a dose of 2 mg three times per day (tid) was associated with a reduction of cerebrospinal fluid (CSF) and peripheral (plasma and serum) viral load among a subgroup of participants completing 6 months of treatment. Baseline and 6-month CSF (n = 92) and peripheral (plasma n = 33; serum n = 24) viral load were measured by the Roche Ultrasensitive assay, version 1.5, with reflexive use of the AMPLICOR assay and preservation of the blind. A DAPTA treatment indicator variable was tested using generalized linear models on change in viral load. Peripheral load (combined plasma and serum) was significantly reduced in the DAPTA-treated group. No group differences in CSF viral load were found. This retrospective study on a limited subgroup of the original trial sample indicated that DAPTA treatment may reduce peripheral viral load without concomitant CSF effects. Future studies should be undertaken to confirm the existence of this result and the CSF-periphery dissociation observed with respect to HIV-1-associated cognitive-motor impairment.

AB - D-Ala1-peptide T-amide (DAPTA) has shown neuroprotection in vitro against gp120-induced loss of dendritic arborization and is promulgated as a CCR5 antagonist. A multisite, randomized, double-blind clinical trial of DAPTA versus placebo prior to combination antiretroviral therapy conducted with human immunodeficiency virus (HIV)-1 seropositive participants having cognitive impairment showed no overall cognitive effect, though subgroups with greater impairment and CD4 cell counts of 201 to 500 cells/mm3 at baseline showed significant improvement. The objective of this study was to examine whether intranasal administration of DAPTA at a dose of 2 mg three times per day (tid) was associated with a reduction of cerebrospinal fluid (CSF) and peripheral (plasma and serum) viral load among a subgroup of participants completing 6 months of treatment. Baseline and 6-month CSF (n = 92) and peripheral (plasma n = 33; serum n = 24) viral load were measured by the Roche Ultrasensitive assay, version 1.5, with reflexive use of the AMPLICOR assay and preservation of the blind. A DAPTA treatment indicator variable was tested using generalized linear models on change in viral load. Peripheral load (combined plasma and serum) was significantly reduced in the DAPTA-treated group. No group differences in CSF viral load were found. This retrospective study on a limited subgroup of the original trial sample indicated that DAPTA treatment may reduce peripheral viral load without concomitant CSF effects. Future studies should be undertaken to confirm the existence of this result and the CSF-periphery dissociation observed with respect to HIV-1-associated cognitive-motor impairment.

KW - Clinical trial

KW - Cognition

KW - CSF

KW - DAPTA

KW - HIV

KW - Peptide T

KW - Viral load

UR - http://www.scopus.com/inward/record.url?scp=33750065423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750065423&partnerID=8YFLogxK

U2 - 10.1080/13550280600827344

DO - 10.1080/13550280600827344

M3 - Article

C2 - 16877299

AN - SCOPUS:33750065423

VL - 12

SP - 178

EP - 189

JO - Journal of NeuroVirology

JF - Journal of NeuroVirology

SN - 1355-0284

IS - 3

ER -